Pipeline Insight: Osteoarthritis - The Wait for a DMOAD Continues - Biologics Market Research

Pipeline Insight: Osteoarthritis - The Wait for a DMOAD Continues
Published Date: November 2006
Published By: Datamonitor
Order Code: R313-18112
Price: $11400 Online Download
$22800 Global Site License
Introduction
Osteoarthritis (OA) is characterized by the progressive destruction of articular joints and is a major cause of pain in Western populations. Osteoarthritis is the most common form of arthritis and severely impacts the physical function and day-to-day quality of life of an individual. It also impacts heavily on the economy and it is believed to cost the US alone an estimated $60 billion per year.
Scope of this report
Detailed pipeline analysis of the key osteoarthritis products in development, plus indication-specific drug sales forecasts to 2015
Competitive drug analysis of the late-phase osteoarthritis pipeline, based on clinical and commercial attractiveness
Overview of patient potential and unmet needs in osteoarthritis across the US, 5EU and Japanese markets
Identification of licensing opportunities based on company portfolios and market needs
Research and analysis highlights
The key unmet need in osteoarthritis is disease modification. The early-phase pipeline is dominated by disease-modifying OA drugs (DMOADs), clearly indicating the future direction of the market. With the first DMOAD to market likely to reach blockbuster status, companies should strengthen their R&D potential by focusing efforts on DMOAD research.
The issue of cardiovascular safety remains at the forefront of the COX-2 and traditional NSAID classes. As evidenced by Prexige (lumiracoxib) and Arcoxia (etoricoxib), appropriately designed, large-scale safety studies will be crucial if any COX-2s are to be approved by the FDA and EMEA. Prexige and Arcoxia remain in pre-registration in the US.
Over the next ten years a number of COX-2 inhibitors as well as NSAIDs and corticosteroids, some with novel mechanisms of action and reportedly improved side effect profiles, will enter the market. Success will depend on effective but restrained marketing, product differentiation and strategic out-licensing arrangements.
Key reasons to read this report
Explore the potential of COX-2s such as Novartis' Prexige and Merck's Arcoxia in the osteoarthritis indication
Quantify the future size of and market potential for novel treatments in the osteoarthritis indication
Identify who the key players in the osteoarthritis market will be as well as understanding gaps in the market for potential products